Company intelligence / Profile preview
Concarlo Therapeutics
Brooklyn, New York, United Statesconcarlo.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Lead product targeting the p27 pathway has been validated in numerous tumor types and animal models. The approach aims for low toxicity and efficacy against drug-resistant cancers. Preliminary CMC completed; clinical entry planned within two years from late 2023.
- No published clinical results yet.
- Therapeutic areas
- Oncology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
NYC Economic Development Corporation support for early funding/advisory
Beyond the preview
Go deeper on Concarlo Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Concarlo Therapeutics.